In a strategic move to enhance their immunology portfolio, GSK has announced an agreement to acquire experimental therapy ...

These studies are conducted by individual researchers who have control over the study and its design, as opposed to larger studies conducted by companies or institutions that may have an entire ...

Walk to End Lupus Now® events provide people affected by lupus and their families with the opportunity to come together for one purpose: ending lupus. Join us in San Francisco to walk together to ...

In a new study, researchers identify biomarkers that may predict the efficacy of low-dose IL-2 (Ld-IL2) treatment in people with systemic lupus erythematosus (SLE). IL-2 stands for interleukin-2 – a ...

In a new study, researchers examined four randomized controlled trials of belimumab (Benlysta®) to gain a better ...

Systemic lupus is the most common form of lupus—it’s what most people mean when they refer to “lupus.” Systemic lupus can be mild or severe. Cutaneous lupus erythematosus This form of lupus is limited ...

Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...

The Lupus Foundation of America (LFA) is excited to announce Karen Costenbader, MD, MPH, Lupus Program Director, Brigham and Women’s Hospital, Professor of Medicine at Harvard Medical School, and ...